Innate Pharma (IPHA) Short Interest Ratio & Short Volume → The #1 Crypto That You Don’t Own… Yet (From Crypto 101 Media) (Ad) Free IPHA Stock Alerts $2.69 -0.20 (-6.92%) (As of 06/10/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Innate Pharma Short Interest DataCurrent Short Interest70,200 sharesPrevious Short Interest79,100 sharesChange Vs. Previous Month-11.25%Dollar Volume Sold Short$175,942.26Short Interest Ratio7.2 Days to CoverLast Record DateMay 15, 2024Outstanding Shares80,860,000 sharesPercentage of Shares Shorted0.09%Today's Trading Volume9,831 sharesAverage Trading Volume10,058 sharesToday's Volume Vs. Average98% Short Selling Innate Pharma ? Sign up to receive the latest short interest report for Innate Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartIPHA Short Interest Over TimeIPHA Days to Cover Over TimeIPHA Percentage of Float Shorted Over Time Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. Innate Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/202470,200 shares $175,942.26 -11.3%N/A7.2 $2.51 4/30/202479,100 shares $182,721.00 -2.7%N/A8.8 $2.31 4/15/202481,300 shares $196,746.00 +5.7%N/A7.8 $2.42 3/31/202476,900 shares $221,472.00 -13.7%N/A7.7 $2.88 3/15/202489,100 shares $217,404.00 +13.7%N/A7.6 $2.44 2/29/202478,400 shares $205,408.00 -4.9%N/A4.1 $2.62 Get the Latest News and Ratings for IPHA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter. 2/15/202482,400 shares $212,592.00 +8.4%N/A4.7 $2.58 1/31/202476,000 shares $203,680.00 -0.9%N/A4 $2.68 1/15/202476,700 shares $214,760.00 -8.9%N/A3.7 $2.80 12/31/202384,200 shares $235,760.00 +55.9%N/A3.9 $2.80 12/15/202354,000 shares $130,140.00 -5.9%N/A2.6 $2.41 11/30/202357,400 shares $137,760.00 -4.3%N/A4.3 $2.40 11/15/202360,000 shares $147,600.00 -6.0%N/A4.2 $2.46 10/31/202363,800 shares $151,844.00 +11.5%N/A4.4 $2.38 10/15/202357,200 shares $132,418.00 -8.5%N/A5 $2.32 9/30/202362,500 shares $158,125.00 -3.4%N/A6 $2.53 9/15/202364,700 shares $192,159.00 -1.5%N/A6.7 $2.97 8/31/202365,700 shares $191,324.97 -8.1%N/A5.2 $2.91 8/15/202371,500 shares $206,635.00 -3.8%N/A6.1 $2.89 7/31/202374,300 shares $218,442.00 -1.9%N/A6.8 $2.94 7/15/202375,700 shares $244,511.00 -3.8%N/A6.4 $3.23 6/30/202378,700 shares $242,002.50 +20.0%N/A6.1 $3.08 6/15/202365,600 shares $213,856.00 +9.7%N/A4 $3.26 5/31/202359,800 shares $175,812.00 -4.3%N/A3.8 $2.94 5/15/202362,500 shares $186,875.00 No ChangeN/A3.6 $2.99 10/31/2022147,600 shares $317,340.00 +12.8%N/A12.9 $2.15 10/15/2022130,900 shares $261,800.00 +15.5%N/A12.5 $2.00 9/30/2022113,300 shares $226,600.00 +1.3%N/A12.7 $2.00 9/15/2022111,900 shares $284,226.00 +2.3%N/A13.3 $2.54 8/31/2022109,400 shares $293,192.00 +0.2%N/A6.4 $2.68 8/15/2022109,200 shares $321,048.00 -10.1%N/A5.9 $2.94 7/31/2022121,500 shares $388,787.85 -3.6%N/A6.1 $3.20 7/15/2022126,000 shares $347,760.00 +0.3%N/A4.9 $2.76 6/30/2022125,600 shares $339,120.00 +3.9%N/A4.8 $2.70 6/15/2022120,900 shares $305,877.00 +1.9%N/A4.6 $2.53 5/31/2022118,700 shares $315,742.00 -13.6%N/A6.2 $2.66 5/15/2022137,300 shares $394,051.00 +8.0%N/A6.7 $2.87 4/30/2022127,100 shares $364,777.00 -9.3%N/A5.7 $2.87 4/15/2022140,100 shares $438,513.00 +4.0%N/A6 $3.13 3/31/2022134,700 shares $452,592.00 +105.0%N/A5.3 $3.36Protect Your Bank Account Before It’s Too Late (Ad)For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …Stop right now and do these 3 things to protect yourself 3/15/202265,700 shares $207,612.00 +13.9%N/A1.6 $3.16 2/28/202257,700 shares $196,757.00 -2.5%N/A1 $3.41 2/15/202259,200 shares $219,632.00 -15.6%N/A0.9 $3.71 1/31/202270,100 shares $265,679.00 -15.3%N/A1 $3.79 1/15/202282,800 shares $375,084.00 -22.3%N/A1.1 $4.53 12/31/2021106,600 shares $486,096.00 +247.2%N/A1.3 $4.56 12/15/202130,700 shares $158,105.00 +0.3%N/A0.3 $5.15 11/30/202130,600 shares $151,776.00 -39.8%N/A0 $4.96 11/15/202150,800 shares $263,652.00 +195.4%N/A0 $5.19 10/29/202117,200 shares $99,760.00 +18.6%N/A0 $5.80 10/15/202114,500 shares $85,115.00 -89.5%N/A0 $5.87 9/30/2021137,800 shares $850,226.00 +79.7%N/A0.1 $6.17 9/15/202176,700 shares $427,986.00 +2,456.7%N/A0 $5.58 8/31/20213,000 shares $10,920.00 -45.5%N/A0 $3.64 8/13/20215,500 shares $18,700.00 -35.3%N/A0.3 $3.40 7/30/20218,500 shares $28,220.00 -33.6%N/A0.5 $3.32 7/15/202112,800 shares $41,472.00 +100.0%N/A0.7 $3.24 6/30/20216,400 shares $21,056.00 -61.0%N/A0.4 $3.29 6/15/202116,400 shares $65,764.00 +1,161.5%N/A1.1 $4.01 5/28/20211,300 shares $5,083.00 +225.0%N/A0.1 $3.91 5/14/2021400 shares $1,580.00 -81.8%N/A0 $3.95 4/30/20212,200 shares $9,416.00 -29.0%N/A0.1 $4.28 4/15/20213,100 shares $13,578.00 -55.7%N/A0 $4.38 3/31/20217,000 shares $30,030.00 -6.7%N/A0.2 $4.29 3/15/20217,500 shares $34,275.00 +53.1%N/A0.2 $4.57 2/26/20214,900 shares $21,658.00 -27.9%N/A0.1 $4.42 2/12/20216,800 shares $30,804.00 +385.7%N/A0.2 $4.53 1/29/20211,400 shares $5,740.00 -74.1%N/A0 $4.10 1/15/20215,400 shares $24,516.00 -77.2%N/A0.2 $4.54 12/31/202023,700 shares $102,147.00 -52.5%N/A0.9 $4.31 12/15/202049,900 shares $219,061.00 +91.2%N/A2.5 $4.39 11/30/202026,100 shares $145,116.00 -7.1%N/A1.5 $5.56 11/15/202028,100 shares $133,475.00 -23.2%N/A1.6 $4.75 10/30/202036,600 shares $146,217.00 +21.6%N/A2.5 $4.00 10/15/202030,100 shares $121,002.00 +32.6%N/A2.5 $4.02 9/30/202022,700 shares $87,168.00 -22.5%N/A2.2 $3.84 9/15/202029,300 shares $127,455.00 +70.4%N/A2.9 $4.35 8/31/202017,200 shares $106,812.00 -5.5%N/A2.2 $6.21 8/14/202018,200 shares $119,210.00 -40.9%N/A2.3 $6.55 7/31/202030,800 shares $187,205.48 +76.0%N/A3.3 $6.08 7/15/202017,500 shares $105,175.00 +25.9%N/A2.1 $6.01 6/30/202013,900 shares $88,404.00 -0.7%N/A1.7 $6.36 6/15/202014,000 shares $87,780.00 -23.1%N/A1.4 $6.27 5/29/202018,200 shares $121,030.00 -59.4%N/A1.3 $6.65 5/15/202044,800 shares $300,160.00 +44.5%N/A2.7 $6.70 4/30/202031,000 shares $235,600.00 -13.9%N/A1.9 $7.60 4/15/202036,000 shares $251,100.00 -15.3%N/A2.3 $6.98 3/31/202042,500 shares $320,875.00 -29.9%N/A2.1 $7.55 3/13/202060,600 shares $390,870.00 -5.2%N/A6.5 $6.45 2/28/202063,900 shares $274,770.00 +47.2%N/A2.1 $4.30Protect Your Bank Account Before It’s Too Late (Ad)For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …Stop right now and do these 3 things to protect yourself 2/14/202043,400 shares $298,592.00 +2.4%N/A1.3 $6.88 1/31/202042,400 shares $318,424.00 -1.6%N/A1.2 $7.51 1/15/202043,100 shares $322,388.00 +8.6%N/A1 $7.48 12/31/201939,700 shares $289,016.00 No ChangeN/A0.6 $7.28 IPHA Short Interest - Frequently Asked Questions What is Innate Pharma's current short interest? Short interest is the volume of Innate Pharma shares that have been sold short but have not yet been covered or closed out. As of May 15th, traders have sold 70,200 shares of IPHA short. Learn More on Innate Pharma's current short interest. What is a good short interest ratio for Innate Pharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IPHA shares currently have a short interest ratio of 7.0. Learn More on Innate Pharma's short interest ratio. Is Innate Pharma's short interest increasing or decreasing? Innate Pharma saw a decline in short interest in May. As of May 15th, there was short interest totaling 70,200 shares, a decline of 11.3% from the previous total of 79,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Innate Pharma's short interest compare to its competitors? Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Innate Pharma: Inhibrx, Inc. (3.91%), Mesoblast Limited (0.68%), Humacyte, Inc. (4.64%), Scholar Rock Holding Co. (16.71%), CARGO Therapeutics, Inc. (13.82%), ProKidney Corp. (21.99%), REGENXBIO Inc. (8.14%), Exscientia plc (3.66%), Taysha Gene Therapies, Inc. (9.11%), HilleVax, Inc. (2.98%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Innate Pharma stock? Short selling IPHA is an investing strategy that aims to generate trading profit from Innate Pharma as its price is falling. IPHA shares are trading down $0.20 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Innate Pharma? A short squeeze for Innate Pharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IPHA, which in turn drives the price of the stock up even further. How often is Innate Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IPHA, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Inhibrx Short Interest Mesoblast Short Interest Humacyte Short Interest Scholar Rock Short Interest CARGO Therapeutics Short Interest ProKidney Short Interest REGENXBIO Short Interest Exscientia Short Interest Taysha Gene Therapies Short Interest HilleVax Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:IPHA) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.